These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31094478)

  • 1. Clinical significance of lipohypertrophy without visual and palpable changes detected by ultrasonography of subcutaneous fat.
    Volkova NI; Davidenko IY
    Ter Arkh; 2019 May; 91(4):62-66. PubMed ID: 31094478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipohypertrophy in China: Prevalence, Risk Factors, Insulin Consumption, and Clinical Impact.
    Ji L; Sun Z; Li Q; Qin G; Wei Z; Liu J; Chandran AB; Hirsch LJ
    Diabetes Technol Ther; 2017 Jan; 19(1):61-67. PubMed ID: 28099050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound characterization of insulin induced lipohypertrophy in type 1 diabetes mellitus.
    Bertuzzi F; Meneghini E; Bruschi E; Luzi L; Nichelatti M; Epis O
    J Endocrinol Invest; 2017 Oct; 40(10):1107-1113. PubMed ID: 28452000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoglycemia observed during continuous glucose monitoring in patients with type 2 diabetes mellitus treated by subcutaneous insulin injection.
    Ito H; Abe M; Shinozaki M; Oshikiri K; Yamashita H; Nakashima M; Takaki A; Yukawa C; Furusho M; Antoku S; Mifune M; Togane M
    Diabetes Technol Ther; 2013 Jul; 15(7):586-90. PubMed ID: 23578166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of insulin-induced lipodystrophy in children, adolescents, and young adults with type 1 diabetes mellitus using recombinant human insulin: a cross-sectional study.
    Singha A; Bhattacharjee R; Dalal BS; Biswas D; Choudhuri S; Chowdhury S
    J Pediatr Endocrinol Metab; 2021 Apr; 34(4):503-508. PubMed ID: 33662195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Errors in insulin treatment management and risk of lipohypertrophy.
    Pozzuoli GM; Laudato M; Barone M; Crisci F; Pozzuoli B
    Acta Diabetol; 2018 Jan; 55(1):67-73. PubMed ID: 29098390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of insulin-related lipohypertrophy frequency and risk factors in patients with diabetes.
    Korkmaz FN; Gökçay Canpolat A; Güllü S
    Endocrinol Diabetes Nutr (Engl Ed); 2022 May; 69(5):354-361. PubMed ID: 35697467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.
    Bastyr EJ; Stuart CA; Brodows RG; Schwartz S; Graf CJ; Zagar A; Robertson KE
    Diabetes Care; 2000 Sep; 23(9):1236-41. PubMed ID: 10977012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
    Krzymień J; Kobli T; Nazar M
    Pol Arch Med Wewn; 2010 Nov; 120(11):444-50. PubMed ID: 21102380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Values of ultrasound for diagnosis and management of insulin-induced lipohypertrophy: A prospective cohort study in China.
    Wang W; Huang R; Chen Y; Tu M
    Medicine (Baltimore); 2021 Jul; 100(29):e26743. PubMed ID: 34398053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis.
    Mader JK; Fornengo R; Hassoun A; Heinemann L; Kulzer B; Monica M; Nguyen T; Sieber J; Renard E; Reznik Y; Ryś P; Stożek-Tutro A; Wilmot EG
    Diabetes Technol Ther; 2024 May; 26(5):351-362. PubMed ID: 38215209
    [No Abstract]   [Full Text] [Related]  

  • 18. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
    J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis.
    Ma J; Lei M; Li Y; Zhang X; Cui N; Yang W
    Adv Ther; 2020 Sep; 37(9):3816-3826. PubMed ID: 32671687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.